Proportion of Hospitalizations Preventable with Increased Oral SARS-CoV-2 Antiviral Treatment
Levy, M. E.; Chilunda, V.; Heaton, P. R.; Grzymski, J.; Pawloski, P. A.; Goldman, J. D.; Luo, S.
Show abstract
We estimated the proportion of hospitalizations that could have been averted had all eligible high-risk adults with SARS-CoV-2 infection in a clinical cohort been treated with an oral SARS-CoV-2 antiviral agent early in infection. Among 3,037 patients with risk factors for progressing to severe COVID-19, 946 (31.1%) received an oral antiviral prescription (834 nirmatrelvir and 112 molnupiravir). Only 3.0% of treated patients vs 9.1% of untreated patients were hospitalized (adjusted risk ratio [RR]=0.27; 95% confidence interval [CI]: 0.18-0.41). If all patients had been treated, an estimated 63.3% (95% CI: 50.4-75.1) of hospitalizations within 30 days could have been prevented. This finding is attributed to large gaps in treatment and a strong protective association of antiviral treatment with subsequent hospitalization.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 95%
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 92%
- Usage and awareness of antiviral medications for COVID-19 92%
Similar papers in this journal
- Risk of Post-COVID Conditions among adolescents and adults who received nirmatrelvir-ritonavir for acute COVID-19: a retrospective cohort study 95%
- Outpatient therapies for COVID-19: How do we choose? 93%
- Initial SARS-CoV-2 viral load is associated with disease severity: a retrospective cohort study 91%
Similar papers in this journal
- Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial 91%
- Out-of-Pocket Spending for COVID-19 Hospitalizations in 2020 91%
- COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults 90%
Similar papers in this journal
- An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial 93%
- Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial 92%
- Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers 90%
Similar papers in this journal
- Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults 92%
- COVID-19 Hospitalizations in Five California Hospitals 91%
- Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.